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Abstract
Introduction Shc adapter proteins are secondary messenger
proteins involved in various cellular pathways, including those
mediating receptor tyrosine kinase signaling and apoptosis in
response to stress. We have previously reported that high levels
of tyrosine-phosphorylated Shc (PY-Shc) and low levels of its
inhibitory p66 Shc isoform are strongly prognostic for identifying
both early node-negative and more advanced, node-positive,
primary breast cancers with high risk for recurrence. Because
aberrant activation of tyrosine kinases upstream of Shc signaling
proteins has been implicated in resistance to tamoxifen – the
most widely prescribed drug for treatment of estrogen receptor-
positive breast cancer – we hypothesized that Shc isoforms may
identify patients at increased risk of relapsing despite tamoxifen
treatment.
Methods Immunohistochemical analyses of PY-Shc and p66
Shc were performed on archival primary breast cancer tumors
from a population-based cohort (60 patients, 9 relapses) and,
for validation, an independent external cohort (31 patients, 13
relapses) in which all patients received tamoxifen as a sole
systemic adjuvant prior to relapse.
Results By univariate and multivariate analyses, the Shc
proteins were very strong and independent predictors of
treatment failure in both the population-based cohort
(interquartile hazard ratio = 8.3, 95% confidence interval [CI]
1.8 to 38, P = 0.007) and the validating cohort (interquartile
relative risk = 12.1, 95% CI 1.7 to 86, P = 0.013).
Conclusion These results suggest that the levels of PY-Shc and
p66 Shc proteins in primary tumors identify patients at high risk
for relapsing despite treatment with tamoxifen and therefore with
further validation may be useful in guiding clinicians to select
alternative adjuvant treatment strategies.
Introduction
Tamoxifen, a partial estrogen receptor (ER) antagonist and the
most widely prescribed drug for the treatment of ER-positive
breast cancer, provides a 40% to 50% decrease in the rate of
relapse in this group of patients [1]. The precise mechanism of
tamoxifen action is unknown; however, binding of tamoxifen to
the ER inhibits estradiol activation of the receptor and ER-
dependent proliferation and promotes cellular apoptosis [2,3].
Despite the objective responses or disease stabilization
achieved with tamoxifen treatment in more than 50% of
patients with previously untreated metastatic breast cancer
[4], nearly 100% of metastatic patients and up to 40% of
patients receiving adjuvant tamoxifen will relapse and die [1].
Clearly, there is a need to identify those patients who are at
Δχ2 = change in chi-squared; CI = confidence interval; df = degrees of freedom; ER = estrogen receptor; HR = hazard ratio; IHC = immunohisto-
chemistry; LBA = ligand-binding assay; pLR = partial likelihood ratio; PR = progesterone receptor; PY = tyrosine-phosphorylated; RFS = relapse-free 
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increased risk of relapse even though tamoxifen therapy has
been administered: such patients would be candidates for
chemotherapy or alternative adjuvant therapies such as Her-
ceptin® (Genentech, Inc., South San Francisco, CA, USA) and
tyrosine kinase inhibitors.
Accumulating evidence indicates that active tyrosine kinases
play a major role in innate and acquired tamoxifen resistance
[3,5]. Ligand-bound ER has the ability to activate growth factor
receptors and their downstream kinases through either direct
cellular membrane interactions, as occur with HER2 and insu-
lin-like growth factor receptor, or via downstream phosphoryla-
tion and transactivation events, as occur with the epidermal
growth factor receptor [6,7]. Conversely, crosstalk with these
receptors enhances the sensitivity of the ER to ligand and may
lead to ligand-independent activation [8] or may hypersensi-
tize ER to the normally weak estrogenic effects of tamoxifen
[9].
Three Shc adapter proteins (p46, p52, and p66 Shc) are tyro-
sine-phosphorylated (PY) in response to signaling from ER as
well as from these other growth factor receptors [10-12]. The
PY-Shc proteins play key roles in activating the Grb2-SOS to
Ras to mitogen-activated protein kinase pathway [13-15] and
therefore the levels of PY-Shc might correspond to the likeli-
hood of tamoxifen resistance. In contrast to the other Shc iso-
forms, however, p66 Shc functions as both a feedback
downregulator of growth factor signaling [16,17] and as a crit-
ical facilitator of stress-induced apoptosis [18]. Thus,
decreased tumor expression of p66 Shc may correspond to
both increased likelihood of growth factor-mediated tamoxifen
resistance and resistance to tamoxifen-driven apoptosis.
We hypothesized, therefore, that high levels of PY-Shc and
low levels of p66 Shc in primary tumors may identify patients
with increased risk of relapse despite having received
tamoxifen therapy. Here, we report an affirmative test of this
hypothesis in a population-based cohort and an independent,
external validation cohort of patients, all of whom received first-




Formalin-fixed, primary tumors from 60 patients (9 relapses)
with invasive breast cancer diagnosed between 1985 and
1991 were obtained from the archives of the Department of
Pathology, Roger Williams Medical Center (Providence, RI,
USA). Patients had surgical removal of the primary lesion (fol-
lowed by local radiation if breast-conserving surgery was
employed), and all patients received tamoxifen as the sole sys-
temic adjuvant therapy until time of censorship or disease
recurrence. Of the 60 patients, none was known to be ER-neg-
ative and 55 were ER-positive. ER positivity was defined as a
dextran-coated charcoal ligand-binding assay (LBA) result of
more than 10 fmol/mg protein [19]. Non-relapsing patients
had a mean follow-up of 6.1 years, and relapsing patients had
a mean time to first relapse of 3.4 years (0.08 to 7.4 years).
Validation cohort
Archival, formalin-fixed, paraffin-embedded primary tumors
from 31 patients (13 relapses) were obtained as a subset of
the case-control study by Ma et al. [20]. All patients received
tamoxifen as part of their first course of therapy. No patients
received neoadjuvant chemotherapy or other systemic adju-
vant therapies before disease recurrence. All patients were
ER-positive, defined as more than 10 fmol/mg protein by dex-
tran-coated charcoal LBA or as an immunohistochemical
result of more than 10% nuclear staining with a score of more
than 3 using a monoclonal ER antibody, clone 1D5 (Dako
North America, Inc., Carpinteria, CA, USA). To minimize con-
founding of potential predictive markers by clinicopathological
characteristics, relapsing and non-relapsing patients were
closely matched by ER/progesterone receptor (PR) status,
nodal status, tumor grade, patient age at diagnosis, and tumor
size. Non-relapsing patients had a mean follow-up of 8.7 years,
and relapsing patients had a mean time to first recurrence of
5.3 years (0.5 to 11.2 years).
Antibodies and immunohistochemical analysis
Characterization of the affinity-purified antibodies to PY-Shc
and p66 Shc and the immunohistochemical procedures have
been described previously [21]. An average staining intensity
for all invasive cancer cells in a section was determined
[22,23]: staining intensities of cancer cells were scored on a
scale of 0 to 5 [21] by a scorer blinded to patient outcomes
and clinicopathological characteristics. To accurately reflect
the heterogeneity in the tumor staining, the intensity score was
multiplied by the percentage of invasive cancer cells staining
at each intensity. These results were summed and then divided
by 100 to achieve a scale of 0 (no invasive cancer cells
stained) to 5 (all invasive cancer cells stained maximally). From
the population-based study, a random subset of slides (n =
24) was scored independently by a second scorer blinded
both to patient outcomes and to the other scorer's results. A
concordance of 0.96 between the scorers, with regard to the
assignment of patients to high versus low ratios of PY-Shc to
p66 Shc staining, was observed, with a Pearson correlation
coefficient of 0.80 (P < 0.0001) [21].
Statistical considerations
Statistical calculations were performed using the Stata statis-
tical package (Stata version 8.0; StataCorp LP, College Sta-
tion, TX, USA). Clinicopathological characteristics were
analyzed by univariate log-rank analysis of their Kaplan-Meier
survivor functions. Differences between PY-Shc-to-p66 Shc
ratios in relapsing and non-relapsing patients were tested for
significance by Wilcoxon rank sum test. The ability of PY-Shc
and p66 Shc, as continuous variables, to predict disease
recurrence was analyzed in univariate and multivariate CoxAvailable online http://breast-cancer-research.com/content/8/6/R73
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proportional hazards models with relapse-free survival (RFS)
as an endpoint. RFS was defined as the time from surgical
removal of the tumor until first clinical recurrence or loss to fol-
low-up (censored). Cox models were checked for validity of
proportional hazards assumptions and goodness of fit using
Schoenfeld and Cox-Snell residual analyses, respectively.
Covariate improvement to models was tested for significance
by partial likelihood ratio (pLR) analysis. For visual evaluation
of RFS, Kaplan-Meier survival functions were constructed
using PY-Shc and p66 Shc values dichotomized on their
median values, and differences between the dichotomized
Shc variables were tested by univariate log-rank analysis. All
statistical tests were two-sided, with significance taken as P <
0.05.
Results
In the population-based cohort, univariate log-rank analysis of
RFS identified significant predictive values for nodal status
and tumor stage and values approaching significance for
tumor grade and PR status. In the validation cohort, however,
no clinicopathological characteristic attained predictive signif-
icance (Table 1). This was expected inasmuch as the valida-
Table 1
Clinicopathological characteristics and univariate analysis of ability to predict failure of tamoxifen therapy
Population-based cohort Case-control cohort
RFS RFS
Variable na Percentageb 8 years Pc na Percentageb 8 years Pc
All patients 9/60 15 79 13/31 42 67
Nodal status 9/60 15 0.04 13/28 46 0.30
Negative 4/45 9 85 8/15 53 57
Positive 5/15 33 64 5/13 38 71
AJCC stage 9/60 15 0.16 NDd NDd
12 / 2 8 7 9 2
2a 0/3 0 100e
2b 7/27 26 58
3a 0/1 0 100e
Tumor stage 9/60 15 0.01 13/31 42 0.17
1 2/32 6 93 3/12 25 74
2 4/21 21 55 10/19 53 62
3 3/4 75 50e
4 0/1 0 100
Tumor grade 9/60 15 0.06 13/31 42 0.56
1 0/5 0 100 0/1 0 100
2 2/22 9 82 8/19 45 63
3 7 / 2 6 2 76 9 5 / 1 1 4 07 0
PR status 9/60 15 0.06 13/31 47 0.96
Negative 0/16 0 100 3/6 50 67
Positive 6/36 17 71 10/25 40 67
Age 9/60 15 0.15 13/31 42 0.56
<50 years 2/6 33 83e 2/2 100 100
≥50 years 7/54 13 84 11/29 38 64
a9/60 indicates that there were 9 treatment failures out of 60 patients with known values for the indicated clinical characteristic. bThe percentage 
of treatment failures for the indicated clinical characteristic. cP is given for log-rank (or log-rank trend) univariate analysis. Sensitivity tests 
conducted with missing values provided no evidence for selection bias. dClinical characteristic was not determined. eFor patients with AJCC 
stage 2a and 3a disease and patients less than 50 years old, the RFS is reported at 7 years. For patients with tumor stage 3 disease, the RFS is 
reported at 6 years. AJCC, American Joint Committee on Cancer; PR, progesterone receptor; RFS, relapse-free survival.Breast Cancer Research    Vol 8 No 6    Frackelton et al.
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tion cohort was a subset of patients from a case-control study
in which relapsing and non-relapsing patients had been
closely matched by ER/PR status, nodal status, and tumor size
[20]. The case-control validation cohort, therefore, provided a
means to evaluate the Shc predictive markers with minimal
potential confounding by clinicopathological variables.
Results representative of the immunohistochemical analyses
of primary tumors shown in Figure 1a depict the contrast typi-
cally observed between PY-Shc and p66 Shc staining intensi-
ties in cancer cells from patients who relapsed despite therapy
compared to those who did not. Based on a previously estab-
lished scoring system for Shc staining intensity [21], patients
in both studies who relapsed (irrespective of tamoxifen ther-
apy) had primary tumors with a higher PY-Shc-to-p66 Shc
staining ratio compared to those tumors from patients who did
not relapse (0.31 ± 0.10 versus 0.09 ± 0.02, P = 0.002, and
0.23 ± 0.08 versus 0.05 ± 0.01, P = 0.049, in the population-
based and validation cohorts, respectively; Figure 1b,c).
Consistent with these observations, by univariate Cox propor-
tional hazards analysis, significant increases in risk of relapse
in these tamoxifen-treated patients were observed with
increasing values of the PY-Shc-to-p66 Shc ratio in each
cohort. The increase in risk with PY-Shc-to-p66 Shc ratio can
be appreciated by the large hazard ratio (HR) for the full
observed range of patient scores: 14 (95% confidence inter-
val [CI]) 2.1 to 93, P = 0.006) for the population-based cohort
and 43 (95% CI 4 to 480, P = 0.002) for the validation cohort.
Considering the PY-Shc and p66 Shc variables as mutually
adjusted covariates, rather than constrained as the ratio,
improves model fit considerably [21]. Compared to the ratio in
the present study, PY-Shc and p66 Shc considered together
as covariates improved model fit (by pLR analysis for the sig-
nificance of the change in chi-squared [Δχ2] for n degrees of
freedom [Δdf]: pLR Δχ2 = 6.08, Δdf = 1, P = 0.013) and pro-
vided an HR for the full observed range of Shc values of 240
(95% CI 9.8 to 5,900, P = 0.001) and an interquartile HR of
8.6 in the population-based cohort (Table 2). For the validation
cohort, a full-range HR of 53 (95% CI 1.8 to 1,600, P = 0.02)
and an interquartile HR of 7.7 were observed (Table 2). This
relationship between the Shc scores and relapse in tamoxifen-
treated patients in both studies is easily visualized from the
Kaplan-Meier RFS functions. The median values of the com-
posite PY-Shc and p66 Shc scores from each cohort were
used as a cut point to divide the patients into high- and low-
risk groups. Within 8 years of primary diagnosis, 38% and
50% of high-risk tamoxifen-treated patients in the population-
based and validation cohorts, respectively, relapsed, whereas
only 3.3% and 14% of the low-risk patients, respectively,
relapsed (Figure 2).
Figure 1
Comparison of the PY-Shc-to-p66 Shc ratio in primary tumors as a  function of disease recurrence Comparison of the PY-Shc-to-p66 Shc ratio in primary tumors as a 
function of disease recurrence. (a) Photomicrographs of PY-Shc and 
p66 Shc immunohistochemical staining patterns in primary tumors from 
patients who received tamoxifen and then either relapsed or did not 
relapse. Shc scores are shown in the insets. The left panel shows the 
staining patterns of two patients from the population-based cohort, and 
the right panel shows the staining patterns of two patients from the 
case-control cohort. Total magnification, ×200. (b) The ratio of PY-Shc 
to p66 Shc (Shc ratio), scaled 0 to 1, is shown (mean ± standard error) 
for primary tumors from patients who either relapsed or did not relapse. 
A comparison of the mean Shc ratios for patients in the population-
based study with or without relapses is shown on the left side of the 
column graph (50 no relapses, 9 relapses; *P = 0.002). A comparison 
of the mean Shc ratios for patients in the case-control study with or 
without relapses is shown on the right side of the column graph (18 no 
relapses, 13 relapses; **P = 0.049). (c) Scatter histograms of the Shc 
ratio, on a log scale, observed in the patients' primary tumors as a func-
tion of relapse in the population-based and case-control cohorts. PY-
Shc, tyrosine-phosphorylated Shc.Available online http://breast-cancer-research.com/content/8/6/R73
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By multivariate analysis, the ability of the Shc proteins to pre-
dict relapse despite tamoxifen therapy was independent of
nodal status, AJCC (American Joint Committee on Cancer)
stage (population-based cohort), tumor stage, tumor grade,
PR status, and patient age at diagnosis. Of these clinical vari-
ables, only nodal status remained as a significant covariate
(population-based cohort: P = 0.04; validation cohort: P =
0.04), with the Shc proteins retaining their full prognostic
value and strength (Table 2). Inclusion of nodal status
improved the overall fit of the model, suggesting that it may be
useful as an independent predictive covariate along with PY-
Shc and p66 Shc.
Discussion
In women with ER-positive breast tumors, the high initial
response rate to tamoxifen has made this drug the most widely
prescribed treatment for this group of patients. Aberrant acti-
vation of kinase signaling pathways in invasive breast cancer
cells, however, may play a widespread role in failure of
tamoxifen therapy [3,5]. Such pathways have the potential to
bypass ER-dependent growth of cells or recruit ERs inde-
pendent of ligand activation through crosstalk, thus facilitating
a resistant phenotype while confounding the predictive utility
of standard clinical markers. Therefore, it is not surprising that
many investigators have focused on identifying new molecular
markers that may identify patients with high risk of relapse
despite tamoxifen therapy. Supporting such an approach, the
application of a multimarker predictive model evaluating the
interdependency between ER, PR, HER2/neu, bcl-2, myc, and
tp53 has resulted in superior predictive power for failure of
tamoxifen therapy, compared to standard marker evaluations
alone [22].
In another approach, the expression levels of large numbers of
genes have been used to predict disease outcome [23].
Despite the promising results obtained from these microarray
gene analyses-based studies, increased costs and complex
methodology may limit their widespread application. Addition-
ally, gene-expression analysis does not measure the actual
level of protein expression, post-translational modification, or
Table 2
Multivariate analyses of ability of Shc proteins to predict failure of tamoxifen therapy
Population cohort Case-control cohort
Model HRa (95% CI) Pb RRa (95% CI) Pb
PY-Shc, p66 Shc 8.6 (2.6–30) 0.001 7.7 (1.4–44) 0.022
PY-Shc, p66 Shc
Adjusted for nodal status 8.3 (1.8–38) 0.007 12.1 (1.7–86) 0.013
aHR (interquartile) is the RR of relapse comparing patients in the 75th percentile of PY-Shc and 25th percentile of p66 Shc to patients in the 25th 
percentile of PY-Shc and 75th percentile of p66 Shc. The multivariate Cox model containing PY-Shc and p66 Shc was adjusted for nodal status, 
AJCC (American Joint Committee on Cancer) stage (population-based cohort), tumor stage, tumor grade, progesterone receptor status, and 
patient age at diagnosis. bSignificance using Wald statistic. CI, confidence interval; HR, hazard ratio; PY-Shc, tyrosine-phosphorylated Shc; RR, 
relative risk.
Figure 2
Relapse-free survival (RFS) according to Shc in patients with breast  cancer Relapse-free survival (RFS) according to Shc in patients with breast 
cancer. (a) Kaplan-Meier graphical analysis of RFS in patients from the 
population-based cohort partitioned by the median value for Shc (P = 
0.013). (b) Kaplan-Meier graphical analysis of RFS in patients from the 
case-control cohort partitioned by the median value for Shc (P = 
0.035).Breast Cancer Research    Vol 8 No 6    Frackelton et al.
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aberrant subcellular localization in the invasive cancer cells,
potentially limiting this methodology's accuracy for predicting
individual patient risk.
In this study, we analyzed the expression and post-transla-
tional modification of Shc adapter proteins in two independent
cohorts of patients with breast cancer by a semi-quantitative
immunohistochemistry (IHC) staining method and found the
Shc proteins to be strongly predictive for disease recurrence
in tamoxifen-treated patients. Primary tumors of these patients
who subsequently relapsed contained characteristically higher
levels of PY-Shc, lower levels of p66 Shc protein, or both com-
pared to primary tumors of those patients who did not relapse.
In Cox survival models, the levels of PY-Shc and p66 Shc
could be modeled as the ratio of PY-Shc to p66 Shc or (more
effectively) as linked continuous covariates, showing a very
strong ability to predict patient outcome (Table 2). These
observations support the hypothesized molecular model of
tamoxifen resistance, in which PY-Shc and p66 Shc subserve
at least partially opposing molecular functions.
Although the predictive ability of markers is most robust when
their expression can be considered as continuous variables
[24], categorizing the Shc scores into groups with high and
low risk of relapse despite tamoxifen therapy is useful for com-
paring RFS curves (Figure 2). By univariate log-rank analysis,
RFS for high- and low-risk groups in each cohort was signifi-
cantly different. Tamoxifen-treated patients with tumors having
a high PY-Shc and/or low p66 Shc score experienced a sig-
nificantly shorter RFS compared to tamoxifen-treated patients
with tumors having a low PY-Shc and/or high p66 Shc score.
Discussions of multimarker prediction models often present
HRs or relative risks (RRs) that represent the full range of risk
over which the model can assign patients. A clinically more
informative measure, however, is the interquartile RR: the
range of risk that can be observed within the middle 50% of
patients. The Shc proteins assigned a very wide range of risk
of relapse over the middle 50% of patients, with an interquar-
tile RR of 8 (Table 2) in the population-based cohort and 12
(Table 2) in the validation cohort. The validation cohort was a
subset of the case-controlled patients studied by Ma et al.
[20], and its Shc interquartile RR of 12 is comparable to the
RR of 7 reported by Ma et al. [20] for the expression ratio of
HOXB13/IL-17BR receptor in a multivariate model for these
same patients.
In multivariate analysis, the ability of the Shc proteins to predict
relapse in tamoxifen-treated patients was strong and inde-
pendent of all potential covariates. Of these, only nodal status
remained as a marginally significant covariate in each cohort,
with the Shc proteins retaining their full prognostic value and
strength (Table 2). Inclusion of nodal status improved the over-
all fit of the model, suggesting that it may be useful as a pre-
dictive covariate along with PY-Shc and p66 Shc. Consistent
with our previous report [21] of the Shc proteins predicting
outcome for both node-negative and node-positive patients,
neither by analysis of correlation nor interaction in the Cox
model was there evidence of association between the Shc
proteins and nodal status. The independence of nodal status
as a predictor is also consistent with the findings of a large
meta-analysis in which node-positive compared to node-nega-
tive patients were shown to have approximately twice the
absolute risk of failing tamoxifen therapy [1].
Other potential covariates may attain significance when larger
study populations are examined. For example, to the extent
that HER2/neu overexpression and activation [3,25] correlate
with both tamoxifen resistance and its activation signals
through Shc-associated pathways, the predictive value of Shc
may occur, in part, due to its capacity as a downstream
reporter of HER2/neu activity. However, HER2/neu is acti-
vated in only approximately 16% of ER-positive patients [26].
For the majority of cases of tamoxifen resistance, the specific
etiology remains unknown, although there is some evidence
that tamoxifen-induced apoptosis may play a role [27]. Addi-
tionally, in other studies, we have observed that the ability of
Shc proteins to predict patient outcome is independent of
HER2/neu expression levels (unpublished data).
All of the patients' tumors in these studies expressed ER as
determined by LBA. Tumors that are ER-positive by LBA con-
stitute approximately 90% of breast tumors that are ER-posi-
tive, as judged by currently used, more sensitive IHC assays
[28,29]. It will be important in subsequent large validation
studies to determine whether the Shc proteins are similarly
able to predict relapse after tamoxifen therapy for this small
subgroup of patients whose tumors express low amounts of
ER.
The difference in incidence of relapse in the population-based
study (15%, 9/40) and the higher incidence in the validation
study (42%, 13/31) reflects the fact that the validation cohort
is a subset of the Ma et al. [20] case-control study, in which
equal numbers of relapsing and non-relapsing patients were
selected based on closely paired clinicopathological charac-
teristics. This approach was implemented to minimize variable
heterogeneity that could potentially confound the analysis of
the predictive abilities of Shc proteins. The case-control
design provided ample statistical power with a minimal total
number of patients in which to validate our primary hypothesis
generated from the population-based study: namely, that the
Shc proteins identify patients at high risk of relapse despite
tamoxifen therapy. However, this selection procedure does not
make possible an exact comparison of the magnitude of the
predictive abilities of the Shc proteins (HR and RR) between
the two studies. Despite this, the significant and very strong
RR in the case-control cohort affirms the results of the popu-
lation-based study showing the predictive independence ofAvailable online http://breast-cancer-research.com/content/8/6/R73
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the Shc proteins from potentially confounding clinicopatholog-
ical characteristics.
Conclusion
The very strong and independent ability of the Shc proteins to
predict disease relapse despite tamoxifen treatment reported
here, coupled with their well-validated ability to predict relapse
in untreated patients, provides a compelling argument for vali-
dating these results in larger patient cohorts and randomized
trials capable of determining the ability of the Shc proteins to
predict tamoxifen benefit. Furthermore, compared to gene
array-based methodologies, the application of state-specific
antibodies in a standardized immunohistochemical analysis
provides a practical and cost-effective approach with the
advantage of evaluating post-translational protein modifica-
tions in addition to expression levels. Upon further successful
validation of these results, high PY-Shc and low p66 Shc
expression levels in primary tumors should be clinically useful
in predicting patients at high risk of relapse despite tamoxifen
therapy and thus in identifying those patients who may benefit
from adjuvant chemotherapy or targeted therapies such as
Herceptin® and tyrosine kinase inhibitors. Conversely, low PY-
Shc and high p66 Shc expression levels in primary tumors may
identify patients at low risk of relapse after tamoxifen therapy
and thus spare them the costs and toxicities of additional
treatments.
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